We analyzed the outcomes of autologous stem cell transplantation (ASCT) following high-dose therapy with respect to remission status at the time of transplantation and induction regimen used in 56 consecutive patients with mantle cell lymphoma (MCL). Twenty-one patients received induction chemotherapy with HyperCVAD with or without rituximab (±R) followed by ASCT in first complete or partial remission (CR1/PR1), 15 received CHOP (±R) followed by ASCT in CR1/PR1, and 20 received ASCT following disease progression. Estimates of overall and progression-free survival (PFS) at three years among patients transplanted in CR1/PR1 were 93% and 63% compared with 46% and 36% for patients transplanted with relapsed/refractory disease, respectively. The hazard of mortality among patients transplanted with relapsed/refractory disease was 6.09 times that of patients transplanted in CR1/PR1 (P=.006).
INTRODUCTION
Mantle cell lymphoma (MCL) has the worst prognosis of all non-Hodgkin lymphoma (NHL) subtypes, with the possible exception of peripheral T cell lymphoma [1] . MCL is incurable with conventional therapies, with a median overall survival (OS) of 3-4 years from diagnosis in most series [1] [2] [3] . During the last 10 years, high-dose therapy followed by autologous stem cell transplantation (ASCT) has become an increasingly common treatment for MCL. Initally, ASCT was reserved as salvage therapy for relapsed or refractory disease, but outcomes were poor with this strategy [4, 5] . In these studies, less heavily pre-treated patients had a longer duration of progression-free survival (PFS), suggesting that ASCT may lead to better outcomes if used earlier in the course of therapy. Subsequent trials assessed ASCT in first complete (CR1) or partial (PR1) remission, and although follow-up was generally short, compared to the earlier trials the median OS improved to approximately 5-6 years [6] [7] [8] [9] [10] [11] [12] , and some studies demonstrated plateaus on the PFS curves, suggesting possible curability [8, 9, 13, 14] .
The first prospective evidence showing a benefit for ASCT in first remission compared with conventional chemotherapy alone came from a trial by Dreyling et al. [15] They reported that patients randomized to induction therapy with a CHOP-like regimen followed by ASCT in CR1/PR1 had an improved median PFS (39 mo. vs. 17 mo., P = .01) compared with patients who received chemotherapy followed by interferon maintenance.
Anthracycline-containing induction regimens appear to lead to the best response rates and longest response durations for MCL [16] [17] [18] [19] [20] [21] , with the most commonly employed regimens being HyperCVAD (fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone, alternating with cycles of high-dose methotrexate and cytarabine) with or without rituximab (±R), or CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) (±R) [20, 21] . No randomized trials have compared these regimens, but limited retrospective data suggest that HyperCVAD may be superior to a CHOP-like regimen before ASCT [22, 23] . We reviewed outcomes after ASCT at our institution with respect to remission status at the time of ASCT, as well as induction regimen, with particular attention to HyperCVAD (±R) vs. CHOP (±R), to assess differences in PFS and OS and to examine prognostic factors.
PATIENTS, MATERIALS, AND METHODS

Selection of Patients
Consecutive patients with a confirmed diagnosis of MCL treated with ASCT between August 1996 and July 2006 were included. Forty-eight of 56 patients had evidence of the (11;14) translocation either by polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH), or cyclin D1 overexpression by immunohistochemistry, whereas 8 patients were diagnosed strictly based on histological appearance and immunophenotypic profile (CD5+, CD20+, CD23-) as outlined by the World Health Organization [24] . Patients were required to have acceptable organ function, performance status, and otherwise be deemed transplantation candidates by their primary oncologist. ASCT was performed at the Fred Hutchinson Cancer Research Center, the University of Washington Medical Center, or the Puget Sound Veterans Affairs Medical Center. Patients who received tandem ASCT followed by allogeneic stem cell transplantation were excluded from this analysis.
Treatment and Monitoring
Newly diagnosed patients were treated with induction chemotherapy with a variety of regimens, according to the preference of their primary oncologist. Most patients received either CHOP (±R) or HyperCVAD (±R) alternating with high-dose methotrexate (MTX) and cytarabine (Ara-C). The induction regimens used in the group of patients who subsequently underwent ASCT with relapsed or refractory disease (Group 3 under the Statistical Analysis section) were: CHOP (±R) (11 patients), CVP (±R) (3 patients), fludarabine (±R) (2 patients), R-HyperCVAD (1 patient), R-EPOCH (1 patient), antisense Bcl-2 inhibitor (1 patient), and local neck radiotherapy (1 patient). Some patients were referred to the transplant service for ASCT in CR1 or PR1, while others were referred after salvage therapy for relapsed/refractory disease. All patients underwent stem cell collection by apheresis after mobilization with filgrastim with or without chemotherapy. Patients were then treated with high-dose therapy followed by infusion of cryopreserved autologous peripheral blood stem cells. The conditioning regimens used were total body irradiation (TBI) with cyclophosphamide and etoposide (23 patients); iodine-131-labelled tositumomab alone (7 patients), or in combination with cyclophosphamide and etoposide (12 patients) or fludarabine (1 patient); and BEAM (BCNU, etoposide, cytarabine, and melphalan) or bulsulfan, thiotepa, and melphalan (13 patients). Stem cell products of selected patients with evidence of peripheral blood involvement by MCL prior to stem cell collection underwent ex vivo purging by immunoaffinity selection of CD34+ cells. The stem cell product of 1 patient underwent B-cell depletion in addition to ex vivo purging. Patients were observed for transplantrelated toxicities in the immediate post-transplant period and then referred back to their primary oncologists for monitoring. Twenty-five patients were treated with post-ASCT rituximab maintenance therapy of varying schedules.
Statistical Analysis
Estimates of OS and PFS were obtained with the method of Kaplan and Meier and calculated from the time of transplant. The probability of relapse was summarized using cumulative incidence estimates, where death without relapse was regarded as a competing risk.
Comparisons of the hazard of failure for OS and PFS were made using Cox regression. followed by ASCT in CR1/PR1; Group 2: CHOP (±R) followed by ASCT in CR1/PR1; and Group 3: ASCT with relapsed or refractory disease. Three patients in the CHOP group received an additional chemotherapy regimen in PR1 in an unsuccessful attempt to achieve a CR and were considered to be in PR1 at ASCT. A fourth patient in the CHOP group achieved a CR after 2 additional cycles of chemotherapy (R-HyperCVAD) in PR1 and was considered to be a CHOP patient in CR1 at ASCT. Groups 1 and 2 were then combined to analyze the differences between patients who underwent ASCT in CR1/PR1 and patients who underwent ASCT with relapsed or refractory disease (Group 3), and the impact of CHOP vs. HyperCVAD among patients transplanted in CR1/PR1 was assessed by comparing Groups 1 and 2.
Responses were determined according to the International Working Group criteria [25] . The pretreatment serum lactate dehydrogenase (LDH) values of several patients who underwent induction therapy at other institutions were not available. For these patients, the International Prognostic Index (IPI) scores were calculated assuming a normal LDH value; thus, the IPI scores may be underestimated for those patients.
Factors other than remission status at ASCT and induction regimen were assessed for their association with outcome. These factors included age at diagnosis, sex, stage at diagnosis, serum LDH at diagnosis, performance status at diagnosis, IPI score, presence of bone marrow or Baseline characteristics were similar among the primary comparison groups, with a few exceptions. A higher percentage of patients treated with CHOP (±R) followed by ASCT in CR1/PR1 had B symptoms (67%) than patients treated with HyperCVAD (±R) followed by ASCT in CR1/PR1 (38%) or patients with relapsed/refractory disease at the time of ASCT (25%). A slightly higher percentage of patients in the CHOP group had a performance status of 2 or greater compared with patients in the HyperCVAD group (13% and 0%, respectively). More patients with relapsed/refractory disease at ASCT had an IPI score at diagnosis of 2 or greater than patients transplanted in first remission (75% and 50%, respectively).
Response to Induction
With respect to the 3 comparison groups, 21 patients were treated with a HyperCVAD (±R) regimen followed by ASCT in CR1/PR1, 15 patients were treated with CHOP (±R) followed by ASCT in CR1/PR1, and 20 patients underwent ASCT with relapsed/refractory disease (Table I) .
Among the 21 patients in the HyperCVAD group, 17 (81%) had a complete response or complete response unconfirmed (CR/CRu) to induction, compared with only 4 of 15 patients (27%) in the CHOP group (P = .002). Among patients who underwent ASCT after relapse, 15 (75%) had a response to initial induction therapy (7 CR/CRu, 8 PR), 3 patients had stable disease, and 2 had progressive disease (Table II) Patients who underwent ASCT in CR1/PR1 had an estimated 3-year OS of 93% compared to 46% for patients who were transplanted with relapsed/refractory disease ( Figure 2 ). PFS at 3 years was estimated to be 63% and 35%, respectively, in these 2 groups of patients. Risk of mortality and risk of PFS failure were increased among patients undergoing ASCT with relapsed/refractory disease compared to patients transplanted in CR1/PR1 (HR 6.09 [95% CI 1.66-22.30], P = .006, and HR 3.15 [1.28-7 .71], P = .01, respectively).
Given the low number of deaths among patients transplanted in CR1/PR1 (2 in the CHOP group and 1 in the HyperCVAD group), a statistical comparison of mortality between these 2 induction regimens is not meaningful. Among patients treated with HyperCVAD (±R) followed by ASCT in first remission, the median OS and PFS have not been reached. Among patients treated with CHOP (±R) followed by ASCT in CR1/PR1, the median OS was not yet reached, and the median PFS was 33.2 months. The estimated 3-year PFS was 81% for patients in the HyperCVAD group and 44% for patients in the CHOP group (Figure 3) . The hazard of failure for PFS among CHOP (±R) patients transplanted in CR1/PR1 was 3.67 (95% CI 0.77-18.24) times that of patients in the HyperCVAD group, but this difference did not reach statistical significance (P = .11).
One patient in the relapsed/refractory group developed a melanoma 5 years after ASCT.
Excluding non-melanoma skin malignancies, no other secondary malignancies were reported among the study patients after ASCT.
Prognostic Factors Other than Induction Regimen and Remission Status at Transplant
A number of factors other than induction regimen and remission status at transplant were examined for their association with overall mortality and failure for PFS (Table III) . Because of the limited number of events (13 deaths, 20 deaths or relapses), the number of factors that could be included in any regression model is limited. In univariate models for overall mortality, elevated LDH was associated with an increased risk of death (44%, compared to 0%, P = .0002).
Patients with an IPI of 0-1 were less likely to die compared to patients with higher IPI scores The same factors listed above associated with mortality were associated with PFS (Table IV) .
Additionally, a better response to induction was associated with improved PFS; patients achieving a PR as opposed to a CR had a hazard ratio (HR) of 5.88 for relapse or mortality (1.67-20.67, P = .006), and patients that did not achieve either a CR or PR had a HR of 16.43 (3.51-76.84, P = .0004). Adjusting for IPI or use of rituximab during induction did not change the conclusion with respect to the association seen between remission status at ASCT and PFS, although the magnitude of the association was reduced (HR 2.73, P = .03 after adjusting for IPI; HR 2.62, P = .04 after adjusting for rituximab). The association fell below the level of statistical significance after adjusting for conditioning regimen (HR 2.46, P = .08), as it did after separately adjusting for rituximab use following ASCT (HR 2.30, P = .10). No other factors examined were statistically significantly associated with the risk of relapse/mortality.
DISCUSSION
Historically, the use of ASCT in patients with MCL began as a salvage therapy for relapsed or refractory disease, although it later became clear that survival results were poor with this approach [4, 5, 26] . Several studies subsequently emerged suggesting improved clinical outcomes for patients transplanted in first remission compared with historical controls or patients receiving delayed transplants [8, [27] [28] [29] . This evidence was supported by a prospective trial showing improved PFS for patients randomized to ASCT rather than interferon maintenance following induction chemotherapy [15] . Based on these data, and encouraged by technical advances in the management of complications related to stem cell transplantation, ASCT as consolidation therapy in first remission has become the preferred treatment for MCL for many oncologists and hematologists, although this practice remains controversial.
In this study we evaluated outcomes of patients with MCL after ASCT with respect to their remission status at the time of transplant and the induction regimen they received. We found that patients who underwent ASCT in first remission had significantly better OS and PFS after ASCT compared to patients who had relapsed/refractory disease at ASCT. Although more patients with relapsed/refractory disease had an IPI score greater than 2 compared with patients in CR1/PR1 at ASCT, this did not appear to account for the observed difference between the groups, as a multivariable analysis adjusting for IPI continued to show an OS and PFS benefit for the patients transplanted in first remission. The OS benefit also remained significant after adjusting for conditioning regimen, although the PFS benefit was reduced. We also found that patients achieving less than a CR with induction therapy had a significantly higher risk of mortality compared with patients who achieved a CR.
These results, along with studies demonstrating better outcomes among patients transplanted in CR1 as opposed to PR1 [23, 27] , highlight the importance of optimizing the initial response to chemotherapy and remission status at ASCT. It is important to emphasize that the current data do not, and cannot, address the question of whether ASCT is preferred over not being transplanted, and found a 4-year disease-free survival of 68% for patients treated with HyperCVAD compared with 33% for patients treated with a CHOP-like regimen [22] . In a more recent abstract by Vose et al. of 80 patients who underwent ASCT in CR1/PR1, patients who were treated with a HyperCVAD (±R) induction regimen had a significantly better 3-year OS (97% vs. 68%) than patients who were treated with a CHOP-like (±R) induction regimen [23] . Additionally, a subset analysis of a study by Ganti et al. suggested that a HyperCVAD (±R) induction regimen was associated with fewer relapses [30] .
In this study we compared the outcomes of patients treated with ASCT in CR1/PR1 after receiving either a HyperCVAD/MTX-Ara-C (±R) or CHOP (±R) induction regimen. A statistical comparison of these 2 groups with respect to OS is difficult, since there were only 3 deaths among patients transplanted in first remission (2 in the CHOP group and 1 in the HyperCVAD group). With regard to PFS, however, there was a higher risk of failure among patients in the CHOP (±R) group, primarily through a higher risk of relapse, compared to those treated with HyperCVAD (±R). The difference did not reach statistical significance, but the power to detect such a difference was limited by the small number of events. That the estimated 3-year OS and PFS of patients in this group were very similar to those reported by Vose et al., however, increases one's confidence that this PFS trend reflects a true superiority of HyperCVAD (±R) in MCL. Furthermore, there was a significantly better CR/CRu rate among patients in the HyperCVAD group compared with those in the CHOP group (81% vs. 27%). As with any retrospective study, however, there were limitations. For example, more patients in the CHOP group had high-risk disease based on IPI score, and fewer patients received rituximab as part of induction compared with patients in the HyperCVAD group, which may have contributed to their lower CR rate with induction and PFS. We must also acknowledge that the median follow-up of patients in the CHOP group is longer than patients in the HyperCVAD group, and that it is possible that this difference might have influenced our findings. The above differences mainly reflect changes in treatment preference over time; in the earlier years of the study, more patients received a CHOP (±R) induction regimen, with fewer patients receiving rituximab, whereas in more recent years, patients were more frequently treated with a HyperCVAD induction regimen that included rituximab.
Although HyperCVAD appears to be associated with higher toxicity than CHOP [16, 20, 21] and requires hospitalization for infusion, it was not associated with a higher rate of mortality during subsequent transplantation. Only one patient died without a preceding relapse (1.8% non-relapse mortality). It should be noted, however, that patients who died during induction or were otherwise not able to tolerate ASCT were not included in this study. The incidence of secondary malignancies was 1 of 56 (1.8%), though a longer follow-up time will be needed to address this concern adequately. An unresolved question concerning MCL is whether ASCT is curative. Previous series present conflicting results, with some studies showing apparent plateaus on PFS curves, whereas others do not [6] [7] [8] [9] [10] [11] [13] [14] [15] 28, [31] [32] [33] . Nevertheless, it is clear that many patients achieve long-term disease-free intervals following ASCT in first remission. One patient on this study remains in a molecular CR more than 10 years after ASCT, and is likely cured. Further studies are needed to identify pre-treatment characteristics predictive of long-term survival with induction plus ASCT or intensive induction alone.
In conclusion, the results of this study suggest that treating MCL patients with ASCT in first remission affords a survival benefit when compared to ASCT after relapse or progression. Our data also show that among patients who are transplanted in CR1/PR1, those who receive HyperCVAD (±R) followed by ASCT may have improved PFS compared to those treated with CHOP (±R) followed by ASCT. In view of the higher toxicity and need for hospitalization associated with the HyperCVAD regimen, randomized trials to confirm these results are warranted. (23) 3 (14) 10 ( .01 FIGURE LEGENDS Figure 1 . Kaplan-Meier estimates of overall survival, progression free-survival, and relapse for the entire cohort. The probability of survival, progression-free survival, and relapse at 3 years were 72%, 52%, and 45%, respectively. for patients treated with HyperCVAD (±R) followed by ASCT in CR1/PR1 were 94% and 81%, respectively, compared with 92% and 44%, in patients treated with a CHOP (±R) regimen followed by ASCT in CR1/PR1. Patients who received a different induction regimen or underwent ASCT with refractory disease or after relapse had the lowest OS and PFS at 46% and 36%.
